TY - JOUR
T1 - Prevalence and Correlates of Electrocardiographic Abnormalities in Adults with HIV
T2 - Insights from the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)
AU - Bloomfield, Gerald S.
AU - Weir, Isabelle R.
AU - Ribaudo, Heather J.
AU - Fitch, Kathleen V.
AU - Fichtenbaum, Carl J.
AU - Moran, Laura E.
AU - Bedimo, Roger
AU - De Filippi, Christopher
AU - Morse, Caryn G.
AU - Piccini, Jonathan
AU - Zanni, Markella V.
AU - Lu, Michael T.
AU - Hoffmann, Udo
AU - Grinspoon, Steven K.
AU - Douglas, Pamela S.
N1 - Funding Information:
G.S.B. has received a grant from NIH/NIMHD R01MD013493 outside the submitted work. HR has received grants from NIH/NHLBI HL123339 and KOWA Pharmaceuticals during the conduct of the study and grants from NIH/NIAID AI068634, NIH/NIAID AI123001, NIH/NHLBI HL137562, and NIH/NHLBI HL146199 outside the submitted work. K.V.F. has received nonfinancial support from American College of Cardiology and International AIDS Society and personal fees from Gilead Sciences, Inc, outside the submitted work. C.J.F. has received grants from Gilead Sciences during the conduct of the study and grants from ViiV healthcare, Janssen, Merck, Cytodyn, Amgen, and Abbvie outside the submitted work. J.P. has received grants for clinical research from Abbott, American Heart Association, Association for the Advancement of Medical Instrumentation, Bayer, Boston Scientific, and Philips and serves as a consultant to Abbott, Abbvie, Ablacon, Altathera, ARCA Biopharma, Biotronik, Boston Scientific, Bristol Myers Squibb, LivaNova, Medtronic, Milestone, ElectroPhysiology Frontiers, Pfizer, Sanofi, Philips, and Up-to-Date. M.V.Z. has received a research grant from Gilead Sciences during the conduct of the study. M.T.L. has received research grants from NHLBI U01 HL123339 and Kowa during the conduct of the study; and from AstraZeneca CT core laboratory for clinical trials outside the submitted work. U.H. has received research grants from KOWA on behalf of the institution during the conduct of the study, personal fees from Duke University, consulting fees from Recor Medical, and grants from KOWA, AstraZeneca, Medimmune, HeartFlow on behalf of MGH outside the submitted work. S.K.G. has received grants from NIH, KOWA, Gilead Sciences, and Viiv during the conduct of the study, personal fees from Theratechnologies Inc, consulting and personal fees from Viiv outside the submitted work. P.S.D. has received grants from KOWA, Gilead Sciences, and Viiv during the conduct of the study. The remaining authors have no conflicts of interest to disclose.
Funding Information:
This study is supported through NIH grants U01HL123336, to the Clinical Coordinating Center, and U01HL123339, to the Data Coordinating Center and funding from Kowa Pharmaceuticals America, Inc., Gilead Sciences, Inc., and ViiV Healthcare. NIAID is supporting this study through grants UM1 AI068636, which supports the ACTG Leadership and Operations Center; UM1 AI068634, which supports the ACTG Statistical and Data Management Center; and UM1 AI106701, which supports the ACTG Laboratory Center. P30DK 040561, KOWA Pharmaceuticals, and Gilead Sciences to SKG. The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the National Heart, Lung, and Blood Institute or the National Institute of Allergy and Infectious Diseases; the National Institutes of Health; or the US Department of Health and Human Services.
Publisher Copyright:
© 2022 Lippincott Williams and Wilkins. All rights reserved.
PY - 2022/3/1
Y1 - 2022/3/1
N2 - Background:People with HIV (PWH) are at increased risk of cardiovasvular disease (CVD) and sudden cardiac death. Previous work has suggested an association between HIV infection and electrocardiographic (ECG) abnormalities. There are limited data on the burden of ECG abnormalities among PWH in a multiracial, multiethnic globally representative population.Setting:One hundred twenty sites in the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE).Methods:ECG findings were grouped into clinically relevant categories using sex-specific thresholds when indicated. We used the Fisher exact tests to assess associations of demographic characteristics and ECG abnormalities. We used logistic regression model to assess associations between demographic and HIV management measures, with adjustment.Results:We analyzed data for 7720 PWH (99% of participants) (median age 50 years, 69% male participants). There were 3346 (43%) Black or African American, 2680 (35%) White, and 1139 (15%) Asian participants. Most of the participants (97%) had viral load that was <400 copies/mL or 400 copies/mL had approximately twice the odds of prolonged QTc compared with those that were undetectable (adjusted OR: 2.05, 95% CI: 1.22 to 3.45).Conclusions:Prolonged QTc is common among male, Asian, and REPRIEVE participants with higher viral loads. These relationships warrant future investigation of linkages to ensuing CVD events among PWH.
AB - Background:People with HIV (PWH) are at increased risk of cardiovasvular disease (CVD) and sudden cardiac death. Previous work has suggested an association between HIV infection and electrocardiographic (ECG) abnormalities. There are limited data on the burden of ECG abnormalities among PWH in a multiracial, multiethnic globally representative population.Setting:One hundred twenty sites in the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE).Methods:ECG findings were grouped into clinically relevant categories using sex-specific thresholds when indicated. We used the Fisher exact tests to assess associations of demographic characteristics and ECG abnormalities. We used logistic regression model to assess associations between demographic and HIV management measures, with adjustment.Results:We analyzed data for 7720 PWH (99% of participants) (median age 50 years, 69% male participants). There were 3346 (43%) Black or African American, 2680 (35%) White, and 1139 (15%) Asian participants. Most of the participants (97%) had viral load that was <400 copies/mL or 400 copies/mL had approximately twice the odds of prolonged QTc compared with those that were undetectable (adjusted OR: 2.05, 95% CI: 1.22 to 3.45).Conclusions:Prolonged QTc is common among male, Asian, and REPRIEVE participants with higher viral loads. These relationships warrant future investigation of linkages to ensuing CVD events among PWH.
KW - HIV
KW - cardiovascular disease
KW - electrocardiography
KW - ethnic groups
UR - http://www.scopus.com/inward/record.url?scp=85124499606&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124499606&partnerID=8YFLogxK
U2 - 10.1097/QAI.0000000000002877
DO - 10.1097/QAI.0000000000002877
M3 - Article
C2 - 35147583
AN - SCOPUS:85124499606
VL - 89
SP - 349
EP - 359
JO - Journal of Acquired Immune Deficiency Syndromes
JF - Journal of Acquired Immune Deficiency Syndromes
SN - 1525-4135
IS - 3
ER -